Skip to main content
. 2020 Feb 12;11(2):e00128. doi: 10.14309/ctg.0000000000000128

Figure 4.

Figure 4.

Treatment pathways in UC incident cohorts for (a) 2008–2011 and (b) 2012–2014. 5-ASA, 5-aminosalicylic acid; IMM, immunomodulator; other Combo Bio, other combination with a biologic; other Combo NonBio, other combination with a nonbiologic; UC, ulcerative colitis.